Physician profile
Raphael Gabay
NPI 1700863743
$3,641.75
in general payments reported to CMS, 2019-2025
11 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $238 · 2021: $518 · 2022: $270 · 2023: $851 · 2024: $108 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,901.64 | 2019-2025 | Xeomin |
| Optinose US, INC. | $446.57 | 2019-2024 | |
| Mentor Worldwide LLC | $142.80 | 2019-2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Galderma Laboratories, L.P. | $29.98 | 2021-2024 | Dysport |
| Acella Pharmaceuticals, LLC | $21.35 | 2024 | NP Thyroid 60 |
| Pacira Pharmaceuticals Incorporated | $21.15 | 2025 | Exparel |
| Motiva USA, LLC | $19.96 | 2025 | |
| Genzyme Corporation | $16.63 | 2022 | |
| Merck Sharp & Dohme LLC | $16.38 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.50 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Gabay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.